This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ASCO® 2020
Presentations
Brentuximab Vedotin | Lymphoma | Abstract TPS8069
Frontline brentuximab vedotin in Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphoma for older patients and those with comorbidities
Brentuximab Vedotin | Lymphoma | Abstract 8032
Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients
Brentuximab Vedotin | Lymphoma | Abstract 8013
Nivolumab and brentuximab vedotin (BV) based, response-adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis
Brentuximab Vedotin | Lymphoma | Abstract TPS8068
Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced stage Hodgkin lymphoma (Trial in Progress)